TP53 and B-cell chronic lymphocytic leukemia: Aplitabart (IGM-8444) (NCT04553692), an IgM DR5 agonist antibody, leverages the apoptotic pathway by binding to death receptor 5 (DR5) to induce programmed cell death in CLL cells, independent of the p53 status, which is crucial in high-risk cases [90].